



NATIONAL
MEDICAL
CANNABIS
UNITY
CONFERENCE
2016



PATIENT ADVOCACY
HARMONIZING MEDICAL
CANNABIS POLICY
AND REALITY
A CONFERENCE ON
HARMONIZATION OF GLOBAL
CANNABIS POLICY AND ACTION



CONFERENCE PROGRAMME

WELCOME TO UNITY 2016!

I am thrilled to welcome you to the Americans for Safe Access 4th Annual National Medical Cannabis Unity Conference. This conference will offer you a learning experience that is unparalleled to any other. This weekend you will be able to meet, network with, and learn from patients, advocates, public health experts, lobbyists, scientists, medical and legal professionals, and other industry associates in the ever-evolving field of medical cannabis.

This year's conference focuses on the Harmonization of Global Cannabis Policy and Action. 2016 will be one of the most significant years for medical cannabis policy ever. A new U.S. President on the horizon and the forthcoming United Nations meetings on Drug Policy, 2016 will offer us a rare opportunity to change laws as well as set policies in motion that can result in safe access to medical cannabis, nationally and internationally.

By attending this Conference, you will become a part of history! On Tuesday, you will get the chance to meet with members of Congress about federal comprehensive legislation. This is a chance to have your opinions be heard by those officials that make decisions that affect our ability to access safe medical cannabis. This year you will also get the unique opportunity to help us prepare a recommendation document that will be a part of the upcoming United Nation meetings on drug policy. This is an extraordinary event that can help achieve our goal of safe and legal access to medical cannabis for everyone.

The momentum is growing! In the last year alone, ASA supporters generated over one hundred thousand emails and signatures for various campaigns nation-wide, ASA trained thousands of patient advocates in civic participation, and our members testified at dozens of public hearings and briefings. For the second year in a row, we helped the Rohrabacher-Farr Amendment, which prohibits the Department of Justice from interfering with those acting in accordance with their state medical cannabis laws, pass in federal legislation. ASA stayed committed to ending the state/federal conflict until it finally paid off.

ASA was honored to play a role in shaping the direction of the Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015. CARERS is the most comprehensive piece of medical cannabis legislation ever introduced in the U.S. Congress. CARERS will protect patients from federal prosecution in states where medical cannabis is legal, reschedule cannabis under federal law, allow legal access to veterans, facilitate research, and more. ASA hosted Senate and Congressional briefings, directly lobbied on Capitol Hill, coordinated over 1000 representative meetings with ASA members, and launched targeted campaigns to key committee members.

Thank you for joining us in Washington, D.C., so that we can celebrate our accomplishments together. It is clear that the federal government's war on patients is drawing to a close, and our members have moved public policy forward by light years through incorporating strategies across many disciplines. Although there is still more work to be done, I am confident that working together, we will be able to overcome barriers to bring safe and legal access to everyone.

Sincerely,



Steph Sherer
Executive Director
Americans for Safe Access

CONFERENCE SCHEDULE

Friday March 18th, 2016	
5:00 pm	Registration Opens (Outside Dolly Madison Ballroom)
8:00 - 10:00 pm	Welcome Reception (Potomac Room)
10:00 pm	Registration Closes (Outside Dolly Madison Ballroom)
Saturday March 19th, 2016	
7:30 am	Registration (Outside Dolly Madison Ballroom)
8:00 am	Exhibit Hall Open (Montpelier A & B)
8:00 - 9:00 am	Breakfast (Montpelier A & B)
9:00 - 9:30 am	Welcome from Steph Sherer, Executive Director of Americans for Safe Access (Dolly Madison Ballroom)
9:30 - 10:00 am	<p>Opening Keynote: History of the Review and Control of Cannabis and Cannabi Resin by Doc. RNDr. Lumír Ondřej Hanuš, MD., Dr.Hcmult (Dolly Madison Ballroom)</p> <p>Dr. Lumír is a Czech analytical chemist and a leading authority in the field of cannabis research. In 1992, he and William Anthony Devane isolated and first described the structure of anandamide, an endogenous cannabinoid neurotransmitter. Lumír Ondřej Hanuš is a research fellow at the Hebrew University in Jerusalem, Israel. He has been awarded honorary Doctoral degrees – including Chemiae Doctor honoris causa (2007) and Medicinae Doctor honoris causa (2011), the Hanuš Medal (2005), the Addictology Award (2012), and Olomouc City Award (2013). His major research interests cover the chemistry of natural products (the isolation and identification of new compounds from plants and animals) and the testing of compounds for biological activity.</p>
10:00 am - 12:00 pm	<p>What Happens When Medical Cannabis is Rescheduled? (Dolly Madison Ballroom)</p> <p>There is no shortage of theories about what the rescheduling of cannabis will accomplish. The rescheduling effort represents an essential step towards stabilizing the cannabis industry and creates opportunities to fast track product development. The effects of rescheduling cannabis to a schedule allowing medical use will be shared along with key insights from both national and international experts.</p> <p>Learning Objectives: Attendees will learn about the history of cannabis scheduling, the mechanisms to reschedule cannabis, and the national and international impacts.</p> <p>Moderator: Jahan Marcu</p> <p>Speakers: Ethan Russo Paval Pachta Steph Sherer Grace Wallack</p>

12:00 - 1:00 pm	Lunch (Montpelier A & B)
1:00 - 3:00 pm	<p>Status of Control of Legal Production of Cannabis for Medical & Scientific Purposes (Dolly Madison Ballroom)</p> <p>Medical Cannabis and hemp cultivation and manufacturing regulations are being implemented around the world. Understanding these regulations is a moving target, and fully understanding these regulations requires a foundation in the basic understanding of the role of 3rd party accreditation/certification bodies and government regulatory agencies. Practical, technical, and legal issues surround the importation and exportation of resinous cannabis and non-resinous hemp products.</p> <p>Learning Objectives: Attendees will learn about the different types of legal cannabis cultivation and production in different parts of the world, including but not limited to United States, Canada, Mexico, Chile, Uruguay, Columbia, Netherlands, Czech Republic, Croatia, Romania, Germany, Italy, Switzerland, Jamaica, Israel, and Australia.</p> <p>Moderator: Steph Sherer</p> <p>Speakers: Pavel Kabu Ras Bobby Morgan Maria de los Angeles Lobos Mark Ware Boaz Wachtel Iain McGregor Tjalling Erkelens</p>
3:00 - 3:30 pm	Break (Montpelier A & B)
3:30 - 5:00 pm	<p>Extracting Flowers, Stalks, Seeds, and DNA: Cannabis Extracts and their Uses (Dolly Madison Ballroom)</p> <p>Different parts of the cannabis plant have different uses and each part can be used for a variety of different applications, but targeting the extraction of different parts of the cannabis plant will yield extracts differing greatly in content. For example, some parts of the plant make better extracts for medicines while other parts are better for isolating DNA for genetic analysis. This panel will discuss the utility of different types of cannabis extracts as well as the differences between the various types of strains and species of cannabis.</p> <p>Learning Objectives: Attendees will learn scientifically accurate names for cannabis varieties, as well as the historical and clinical uses of various extracts and preparations. This will include functional cannabis plant anatomy related to resin production. Different methods of extraction will also be discussed.</p> <p>Moderator: Ethan Russo</p> <p>Speakers: Ryan Lynch Ezra Pryor Melissa Wilcox Jeff Raber Christopher Hudalla</p>

CONFERENCE SCHEDULE

5:00- 6:00 pm	<p>Utilizing ASA Tools for Advocacy and Activism (Dolly Madison Ballroom)</p> <p>There are a number of resources available from ASA to not only help pass, improve, and adopt laws and regulations in your state, but also to educate medical professionals, patients, and family members.</p> <p>Learning Objectives: Attendees will learn more about available resources through ASA programs and about how to utilize those resources in their own advocacy efforts.</p> <p>Moderator: Don Duncan</p> <p>Speakers: Timothy-Paul Murphy Stephen B. Corn, MD Paval Kubu Beth Collins</p>
6:00 - 7:00 pm	Break (Montpelier A & B)
7:00 pm	Exhibition Hall Closes (Montpelier A & B)
7:00 - 9:00 pm	<p>Advocacy & Activism in Scientific Societies & Trade Associations (Dolly Madison Ballroom)</p> <p>There are number of resources available to the medical cannabis industry to improve and adapt to the regulations that will affect your business practices. For example, AHPA, CANN, PFC, A2LA, and AHP are examples of the tools and resources available for advocates related to health and safety standards for cannabis. Various scientific and trade associations are involved with voicing the concerns of their constituents and affecting policy changes. Different aspects of advocacy are available for a wide range of activities including cannabis professional training, laboratory accreditation, clinician education, and updating standards for implementing such criteria.</p> <p>Learning Objectives: Attendees will learn about the resources and partner groups that are important for creating, maintaining, and implementing standards, as well the potential committees and groups to join in order to effectively communicate your message.</p> <p>Moderator: Jahan Marcu</p> <p>Speakers: Franjo Grotenherman, IACM Ezra Pryor, ACS Kristin Nevedal, PFC Mark Blumenthal, ABC Cynthia Ludwig, AOCS Jane Wilson, AHPA Susan Audino, A2LA</p>

Sunday March 20th, 2016	
7:30 am	Registration (Outside Dolly Madison Ballroom)
8:00 am	Exhibit Hall Open (Montpelier A & B)
8:00 - 9:00 am	Breakfast (Montpelier A & B)
9:00 - 11:15 am	<p>Next Generation Research and Innovations in Cannabis Patient Care (Dolly Madison Ballroom)</p> <p>This panel will discuss “How” and “Why” people are using cannabis as a medicine and wellness product. Cannabis has a number of well-known therapeutic uses, but the number of methods and variations by which people can consume the plant have substantially increased over the last few years. New research sheds light on lesser understood disease symptom management as well as rates of use among different populations.</p> <p>Learning Objectives: Attendees will learn about population and clinical studies that examine different types of cannabis use and reported effects. This includes the current extent of therapeutic applications and epidemiology in medical use.</p> <p>Moderator: Marcel Bonn-Miller</p> <p>Speakers: Roy Upton Mark Ware Iain McGregor Dustin Sulak Ethan Russo</p>
11:15 am - 12:30 pm	<p>Reality-Based Cannabis Risk Considerations (Dolly Madison Ballroom)</p> <p>The United States and the world are seeing a rise in the quantity of cannabis products being consumed. This panel discusses the signs of a substance use disorder, disorders associated with exogenous cannabinoid use, potential long-term side effects of using well-known and lesser-known cannabinoids, potential side effects from drug-CBD/THC interactions, and current treatments for cannabinoid side effects, and substance abuse related to the endocannabinoid system.</p> <p>Learning Objectives: Attendees will learn how drug abuse studies are conducted, how to interpret data, and to think critically about controversial data that has a very big impact on shaping public policy.</p> <p>Moderator: Mark Ware</p> <p>Speakers: Marcel Bonn-Miller Ryan Vandrey Jahan Marcu</p>
12:30 - 1:30 pm	Lunch (Montpelier A & B)

CONFERENCE SCHEDULE

1:30 - 3:30pm	<p>Overview of quality assurance of medicinal cannabis (Dolly Madison Ballroom)</p> <p>Quality assurance systems are an integral part of every commercial good and service, and are used in manufacturing everything intended for both human and animal consumption. For the last 3 years, cannabis standards have been adopted in 11 states based on regulatory tools such as Patient Focused Certification (PFC), ISO17025, the American Herbal Products Association (AHPA) Recommendations for Regulators, and the American Herbal Pharmacopoeia (AHP) Cannabis monograph.</p> <p>Learning Objectives: Attendees will learn about the existing standards, and how they were created, updated, and adopted by 11 states for producing safe and reliable cannabis products.</p> <p>Moderator: Mark Bluementhal</p> <p>Speakers: Tjaling Erkelens Roy Upton Kristin Nevedal Susan Audio Ryan Vandrey</p>
3:30 - 4:00pm	<p>Break (Montpelier A & B)</p>
4:00 - 6:00 pm	<p>Stakeholder Document Review</p> <p>Medical Cannabis Patient Stakeholder Document Review Session (Mount Vernon A & B)</p> <p>Cannabis Industry Stakeholder Document Review Session (Constitution B)</p> <p>Veterans Stakeholder Document Review Session (John Adams A & B)</p> <p>Parent Stakeholder Document Review Session (Hamilton A & B)</p> <p>Medical Professional & Researcher Stakeholder Document Review Session (Constitution A)</p>
6:00 PM	<p>Registration Closes (Outside Dolly Madison Ballroom)</p>
6:00 PM	<p>Exhibition Hall Closes (Montpelier A & B)</p>

Monday	March 21th, 2016
7:30 am	Registration (Outside Dolly Madison Ballroom)
8:00 am	Exhibit Hall Open (Montpelier A & B)
8:00-9:00 am	Breakfast (Montpelier A & B)
9:00 - 10:30 am	<p>CBD Only Laws: First Step or Roadblock? (Dolly Madison Ballroom)</p> <p>With 17 out of the 40 states having adopted medical cannabis laws restricting cannabis to Cannabidiol (CBD) rather than the full range of cannabinoids, there is a lot of debate on whether or not this approach is helpful or detrimental to states moving forward with eventual comprehensive legislation. Attendees will learn the various perspectives on passing CBD vs. full medical cannabis legislation and how the political climate in states can influence this approach.</p>
10:30 am - 12:00 pm	<p>Workshop A: State Laws: Perspectives from Patients (Dolly Madison Ballroom)</p> <p>At the beginning of this year, ASA released its annual report: “Medical Marijuana Access in the US: A Patient-Focused Analysis of the Patchwork of State Laws,” which evaluates the array of differing laws across the country from a patient’s perspective. In this interactive session, attendees will learn how state laws are affecting other patients throughout the country and have the opportunity to share their own stories. In addition, participants will receive lobbying tips from some of the most effective patient advocates in the country.</p> <p>Moderator: Beth Collins</p> <p>Speakers: Sebastien Cotte Kate Hintz Jeanne Sauro</p>
10:30 am - 12:00 pm	<p>Workshop B: Drafting and Weighing in on Legislation and Regulations (Constitution A & B)</p> <p>Speakers: Mike Liszewski & Kristin Nevedal</p> <p>Want to add a certain ailment to your state’s qualifying conditions list, but don’t know where to start? Looking to weigh in on rulemaking at the state or local level, but unsure of the best language to use? Need advice on introducing a bill to ensure patients no longer face denial of organ transplants or other life-saving medical care? This workshop is for you! Come learn the in’s and out’s of influencing policymakers from the pro’s in ASA’s policy shop!</p>
12:00 - 1:00 pm	Lunch
1:00 - 2:30 pm	<p>Workshop A: Meeting Facilitation Training (Dolly Madison Ballroom)</p> <p>Speakers: Steph Sherer</p> <p>Hosting successful meetings is an under-appreciated and an often overlooked art. Many advocates spend most of their of resources on turn-out for meetings and overlook preparing for the meeting itself. Most Americans have never been to a political meeting and the experience they have will determine whether or not they remain involved in the organization or possibly even the issue. This training has been created to give you the tools you need run an effective meeting, make that time productive and engaging, and successfully carry out your work.</p>

CONFERENCE SCHEDULE

1:00 - 2:30 pm	<p>Workshop B: Building Relationships with Elected Officials (Constitution A & B)</p> <p>Speakers: Beth Collins</p> <p>Citizen lobbying is an essential part of being a medical cannabis advocate and it is the only way elected officials will know how to represent you. Most elected officials have never met a medical cannabis advocate and have formed opinions about the issue based on media reports or and opposition. It is easier for elected officials to fall into intellectual or ethical stances against medical cannabis if they do not have a face to put with the issue. This workshop is designed to give advocates the tools they need to develop solid relationships with their representatives at all levels of government.</p>
2:30 - 4:00 pm	<p>Workshop A: Citizen Lobbying (Dolly Madison Ballroom)</p> <p>Speakers: Don Duncan</p> <p>Learn the tricks of the trade of having a successful lobby meeting. Everyone who will be lobbying on Tuesday needs to come to this workshop. You will have the chance to practice for your meetings with legislators on Tuesday.</p>
2:30 - 4:00 pm	<p>Workshop B: Intersection of Advocacy & Commerce in the Medical Marijuana Industry (Constitution A & B)</p> <p>Speakers: Steve Berg</p> <p>Advocacy and commerce may seem like strange bedfellows, yet they go hand-in-hand for medical marijuana and safe access. In this workshop, participants will learn how activism and enterprise must collaborate to maximize social impact and make medical cannabis available to all who are in need. Participants will gain perspective on what they can do to improve the policy, regulatory and commercial landscapes.</p> <p>Following a brief review of the historical interplay between cannabis advocacy and commerce, real-life examples of how the twin dynamics are playing out for OpenVAPE , one of the largest brands in the medical marijuana industry, will be featured. Participants will also engage in a hands-on example of how businesses can work with advocates – and vice-versa - to enroll regulatory acceptance and increase the safety and availability of medical cannabis products for patients.</p>
4:00 - 4:30 pm	Break
4:30 - 6:00 pm	<p>Federal Legislation 2016, What is at Stake? (Dolly Madison Ballroom)</p> <p>Americans for Safe Access and other advocates have worked for years to lay the foundations for lasting changes for patients. We're making real progress, but until we pass the CARERS Act, state laws and the people they are intended to protect remain in jeopardy.</p> <p>Learning Objectives: Attendees will learn the difference between policies and laws, the impact CARERS will have on state programs, and what is at risk if we do not pass federal legislation in 2016.</p> <p>Moderator: Mike Liszewski</p> <p>Speakers: Alexander Campbell Steph Sherer John Hudak Stephanie Phillips</p>

6:00 pm	Registration Closes (Outside Dolly Madison Ballroom)
6:00 pm	Exhibition Hall Closes (Montpelier A & B)
7:00 -8:00 pm	VIP Reception (Constitution A & B)
8:00 - 9:30 pm	ASA Excellence Awards Banquet (Dolly Madison Ballroom)

Tuesday

March 22nd, 2016

8:00 am	Registration Opens (Outside Dolly Madison Ballroom)
9:00 -10:00 am	Breakfast (Montpelier A & B)
10:00 -10:30 am	Closing remarks (Dolly Madison Ballroom)
10:30 - 11:00 am	Travel to Capitol Hill
11:30 - 12:30 am	Press Conference and Group Photo on Capitol Hill
12:00 - 4:00 pm	Lobbying on Capitol Hill

CONFERENCE ENRICHMENT COURSES

PFCEC 103 - QA/QC and representative sampling (2 hours)	
Date: March 21, 2016 Time: 10:00 am - 12:00pm Location: Mount Vernon A & B Instructor: Jahan Marcu, ASA Chief Scientist & PFC Chief Auditor Cost: \$100 Conference Attendee Cost: \$50 Credit Hours: 2	This course is required of all PFC auditors regardless of the discipline(s) they will be auditing and is strongly recommended for the management team of medical cannabis businesses. During this course, participants will be provided with an overview of paradigm shifts relating to QA/QC. Details on developing and implementing Quality Assurance (QA) and Quality Control (QC) systems will be discussed, including method validation and General Manufacturing Practices (GMP's). Additionally, this course will explore "representative sampling" techniques and how to apply them to cultivation, processing, and manufacturing operations to ensure consistent product purity and quality.

PFCEC 104 - Auditing operations, sops, & record keeping for compliance (2 hours)	
Date: March 21, 2016 Time: 3:30pm - 5:30pm Location: Mount Vernon A & B Instructor: Jahan Marcu, ASA Chief Scientist & PFC Chief Auditor Cost: \$100 Conference Attendee Cost: \$50 Credit Hours: 2	This course is required for all PFC auditors regardless of the discipline(s) they will be auditing. Designed to familiarize trainees with audit protocols, checklists and documentation audits. This in-person course will be taught using a combination of lecture and hands on exercises. Trainees attending this course will also receive training on etiquette and appropriate protocols for interacting with staff and management at the location being audited as well as organizational techniques necessary for writing a final audit report.



#HumboldtsFinest

COMING SUMMER 2016

Humboldts Finest a Broad Spectrum of PFC
Verified Whole Flower Products Throughout California.



Grown the Way Nature Intended.

SPEAKERS



MARÍA DE LOS ANGELES LOBOS

María de los Angeles Lobos holds a degree in Psychology and has a specialization in dual diagnosis. She is the director of treatment center for problematic drug consumption of Dianova Chile with headquarters in Viña del Mar. Dianova is an international NGO, operates in 11 countries across Europe and the Americas, with programs and projects in the fields of education, youth, addiction prevention and treatment, and in the area of social and community development.

She has focused on gender approach, intervention and treatment for problematic drug consumption on womens.

Her key areas of expertise are gender issues, public policy for the treatment and rehabilitation of people with problematic drug use, HIV / AIDS and addictions, dual pathology and harm reduction.



SUSAN AUDINO

Susan Audino obtained her PhD in Chemistry with an analytical chemistry major, physical and biochemistry minor areas, and met the requirements of an NSF Chemometric Fellowship. She currently owns and operates a consulting firm to service chemical and biological laboratories, is an A2LA Lead Assessor and Trainer, and serves as a Board Member for the Center for Research on Environmental Medicine in Maryland, where she is actively engaged in medical research. Susan has been studying cannabis chemistry for several years, providing scientific and technical guidance to cannabis dispensaries, testing laboratories, medical personnel, and regulatory agencies. Dr. Audino's interest most directly involves marijuana/cannabis consumer safety and protection, promotes active research towards the development of Official Test methods specifically for the cannabis industry, and collaborates with AOAC, AOCS, and other interested parties.



STEVE BERG

Steve Berg is the Chief Financial Officer of O.penVAPE. He manages matters relating to finance, business development, investor relations, corporate strategy, PR and advocacy. In addition to more than 22 years of experience in investment banking and finance, Mr. Berg has been a proponent of medical cannabis for decades. He believes business can be a powerful platform to effect social and legal change. He found his calling after progressing from the world of big banks to working on the front lines of legal cannabis enterprise. Prior to joining O.penVAPE, Mr. Berg was a co-founder of the thriving ArcView Investor Network, where investors, policy groups, and the most promising cannabis companies cast deals to develop future leaders in the industry and expand patient and consumer access. As editor of ArcView Market Research's The State of Legal Marijuana Markets, Second Edition, the cannabis industry's leading independent market research report, Berg is an acclaimed expert on the economics and development of the legal marijuana industry.



MARK BLUMENTHAL

Mark Blumenthal is the Founder and Executive Director of the American Botanical Council (ABC), the leading independent, non-profit organization dedicated to disseminating accurate, reliable, and responsible information on herbs and medicinal plants.

He is the Editor/Publisher of HerbalGram, an international, peer-reviewed quarterly journal. For six years he was an Adjunct Associate Professor of Medicinal Chemistry at the University of Texas at Austin, College of Pharmacy, teaching the course „Herbs and Phytomedicines in Today’s Pharmacy.“ Mark is the Senior Editor of the English translation of The Complete German Commission E Monographs–Therapeutic Guide to Herbal Medicines (1998), Herbal Medicine: Expanded Commission E Monographs (2000), The ABC Clinical Guide to Herbs (2003), and co-author of Rational Phytotherapy, 5th edition (2004). He has appeared on over 400 radio and television shows and has written over 500 articles, reviews and book chapters for many major publications. In 2010 he was awarded the prestigious Tyler Prize in honor of the late Purdue Professor Varro E. Tyler from the American Society of Pharmacognosy.

In 2008 he was awarded the “Natural Legacy” award from Natural Foods Merchandiser magazine and he has also been named to Natural Health Magazine’s Hall of Fame Award for “...opening America’s eye to the healing powers of herbs.” He has been a leader in the concerns for more rational regulations of herbal and natural product manufacturing, and education on plant-based medicines for over 40 years.



MARCEL O. BONN-MILLER

Marcel O. Bonn-Miller, Ph.D., is an Assistant Professor in the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine. He received his B.A. and Ph.D. in Clinical Psychology from the University of Vermont and was a Postdoctoral Fellow at Stanford University School of Medicine. Dr. Bonn-Miller has dedicated his career to understanding the interrelations between cannabis use and PTSD, with the aim of informing intervention and prevention strategies. Dr. Bonn-Miller is internationally recognized as a leading expert in the study of cannabis use among individuals with PTSD. He has received dozens of grants varying in focus from experimental laboratory-controlled to prospective outcome studies, has published well over 100 peer-reviewed empirical publications, and serves on the editorial boards of six scientific journals.



ALEXANDER CAMPBELL

Alexander Campbell is an attorney working and living in Massachusetts, and the author of The Medical Marijuana Catch-22: How the Federal Monopoly on Marijuana Research Unfairly Handicaps the Rescheduling Movement, published in 2015. While in law school, Alex focused heavily on health law and worked at a Federally-Qualified Health Center and a new health insurance company in Boston. Alex currently works for the Commonwealth of Massachusetts.



BETH COLLINS

Beth Collins first became involved in medical marijuana advocacy in 2013 while trying to help treat her daughter Jennifer’s intractable epilepsy. After trying and failing numerous pharmaceutical medications, Beth and Jennifer left her husband and other daughter in Virginia, and moved to Colorado to access cannabis oil to treat Jennifer’s seizures. While in Colorado, Beth began lobbying the Virginia General Assembly for access to medical cannabis. In 2014, Beth and her daughter returned to Virginia and she worked with other parents to pass legislation that allows her daughter to take THCa oil in the state without fear of prosecution. She continues to work with Virginia’s lawmakers to expand access and cultivation in the state.

In addition, Beth helped form and lead the Parents Coalition for Rescheduling Medical Cannabis, a national parent group with the mission of removing cannabis from its current schedule 1 status. She has also lobbied Congress in support of the CARERS Act, the most comprehensive piece of federal medical marijuana legislation ever introduced in both the U.S. House and Senate. In January 2016, Beth joined the staff of Americans for Safe Access in the position of Communications and Outreach Director where she hopes to help advocates initiate, expand, and improve state medical cannabis laws and programs, and work with Federal decision makers to reschedule cannabis and reduce the conflict between state and federal cannabis laws.



STEPHEN B. CORN, MD

Stephen B. Corn, MD is a board certified physician of Brigham and Women’s Hospital and Children’s Hospital, Boston, Massachusetts and Professor at Harvard Medical School. He specializes in anesthesiology, pain and perioperative medicine. He is also a prolific inventor and holds over 30 United States and international patents. His expertise in medical devices has resulted in his being named the first and only “Director of Clinical Innovation” for both Boston Children’s Hospital and Brigham & Women’s Hospital, Harvard Medical School.

Dr. Corn is the recipient of numerous awards and was named, “Champions in Health Care” by the Boston Business Journal. Dr. Corn was featured on CBS News Boston and San Francisco for clinical innovation and inventing a non-contact means to measure breathing and respiratory depression.

Dr. Corn co-founded TheAnswerPage.com in 1998 to provide daily education to doctors and other healthcare professionals. TheAnswerPage is read in over 120 countries, has granted well over 100,000 hours of AMA PRA Category 1 CME Credits™ and offers an industry-unique interactive crossword puzzle for a fun and effective learning experience. TheAnswerPage is a recognized leader in medical marijuana education and the sole provider of the required “New York State Practitioner Education-Medical Use of Marijuana Course” and the Florida Medical Society required state medical marijuana course.

Dr. Corn is proud to note that in 2014, he was named „Medical Professional of the Year” by the Americans for Safe Access (ASA) in Washington, DC.

Dr. Corn has donated technology appraised at over \$6 million to Brigham & Women’s Hospital, Harvard Medical School and Women & Infant’s Hospital, Brown University.



SEBASTIEN COTTE

Sebastien Cotte became actively involved in the field of medical marijuana in 2013 while seeking alternative treatments for his son Jagger who is suffering from a rare terminal genetic disease. Like many other families, Sebastien and his wife Annett became medical refugees in Colorado to access cannabis oil for Jagger but returned to Georgia in late 2015 to focus on the 2016 legislative session and the need for in state cultivation.

He is also completing a medical marijuana certification program offered by Americans for Safe Access and the Cannabis Training Institute. He is not only an active member in the medical marijuana community, but also serves as an ambassador for the United Mitochondrial Disease Foundation, an organization that provides education, awareness and resources to health care professionals, patients and families affected by Mitochondrial disease.

Sebastien is the national business director/board member for the Flowering Hope Foundation (a 501c non for profit that provides education and patient support for Haleigh's Hope products) and he is on the board of advisor for MdHerb, an educational website that focuses on cannabis patients. In his free time, Sebastien is a guest host of the Cannatics political show on Millennium Grown Broadcast Network.



DON DUNCAN

Don Duncan has served on the Board of Directors since he co-founded American for Safe Access in 2002. As California Director, he is coordinating the grassroots and grasstops campaign to fully implement the states medical cannabis laws, respond to federal interference, and build a broader and more powerful coalition for medical cannabis in California. Mr. Duncan was instrumental in galvanizing grassroots resistance to federal raids and in seeding local self-regulatory alliances for medical cannabis providers statewide. He has worked closely with elected officials, law enforcement, collective operators, and community members in local implementation efforts in several California cities and counties, and is currently working with lawmakers in Sacramento to adopt legislation to expand rights for patients.

Mr. Duncan co-founded one of the oldest and most reputable families of medical cannabis dispensing collectives in California, helping to open legal facilities in Berkeley, West Hollywood, and Los Angeles. He is a leading consultant in the field of medical cannabis and has been featured in major media coverage, including 60 Minutes, Dan Rather Reports, Retirement Living TV, and the Los Angeles Times.



TJALLING ERKELENS

Tjalling Erkelens, CEO Bedrocan BV The Netherlands. Born in 1956 in The Netherlands, where he still lives, Tjalling studied to be a teacher before starting his career as a freelance journalist in 1976 , with a particular interest in agriculture and horticulture. In 1984, he married farmer's daughter Wupke Bruining, and together they raised three sons. That same year he and his brother in law, Freerk Bruining, started a horticultural company now known as Bedrocan B.V. Over the years the company developed into a highly specialized, horticultural firm specializing in indoor cultivation and processing of plant material under standardized conditions. In 1992 Tjalling and Freerk started pioneering indoor cannabis grow for he purpose of seed production. In 2003, their work was acknowledged by the Dutch Health Ministry, which awarded Bedrocan the first five-year contract to cultivate medicinal cannabis for distribution through pharmacies. Under Tjallings' leadership the company turned into a multinational with licensed facilities up and running in The Netherlands, Canada and The Czech Republic with a joint annual capacity of about 5500 kilograms of cannabis. While operating under GAP and ISO 9001-2008 standards, the Dutch and Czech facilities are now the first ones to be GMP approved by the health authorities in the respective countries for production of cannabis flos as a fully standardized pharmaceutical raw material.



LUMÍR HANUŠ

Dr. Lumír Ondřej Hanuš is a Czech analytical chemist and a leading authority in the field of cannabis research. In 1992, he and William Anthony Devane isolated and first described the structure of anandamide, an endogenous cannabinoid neurotransmitter. Dr. Hanuš is a research fellow at the Hebrew University in Jerusalem, Israel. He has been awarded honorary Doctoral degrees – including Chemiae Doctor honoris causa (2007) and Medicinae Doctor honoris causa (2011), the Hanuš Medal (2005), the Addictology Award (2012), and Olomouc City Award (2013). His major research interests cover the chemistry of natural products (the isolation and identification of new compounds from plants and animals) and the testing of compounds for biological activity.



JOHN HUDAK

John Hudak is a Senior Fellow in Governance Studies and Deputy Director at the Center for Effective Public Management at the Brookings Institution. His research focuses on presidential power, bureaucratic process, campaigns and elections. He has written extensively on questions of governance, regulation, and administration with regard to marijuana legalization policy. He is the author of the forthcoming book Marijuana: A Short History. John holds a B.A. in political science and economics from the University of Connecticut, and an M.A. and Ph.D. in political science from Vanderbilt University.



PAVEL KUBŮ

Pavel Kubů MD is the expert in the medical informatics and addictology. 2001 graduated in general medicine with a focus on diseases prevention and public health at Charles University in Prague, 3rd Medical Faculty.

Between 2005 and 2015 was working for Intel Corporation as the Business Development Manager. He was leading projects of Intel World Ahead Program for Healthcare in Central and Eastern Europe and Education in the Czech Republic and Slovakia. In 2006 appointed as chairman of the Ethical Commission at the Czech National Monitoring Center for Drugs and Drug Abuse. This government agency is among others responsible for evaluation of ethical conditions and human rights compliance in all R&D project related to illegal drug use requesting public fundings.

Serves since 2007 as the board member of the Czech National Forum for eHealth, between 2012 and 2015 as the steering committee member of Czech Healthcare Forum and from 2013 as the board member of medical cannabis patient organization KOPAC. In March 2015 became founding member of International Medical Cannabis Patient Coalition. He is primarily devoted to education of healthcare professionals, patients and caregivers and support of research and development of new treatment and preventive methods in these non profit NGOs.

Since 2011 leads medical strategy implementation at co-founded company Elon Medical devoted to R&D of wearable plastic electronics actually using printed light and smart nanotechnologies in new treatment methods for dermatology, neonatology, mental health oncology, ophthalmology and surgery.

December 2015 founded with colleagues International Cannabis and Cannabinoids Institute and become Chief Executive Officer of research and innovation hub focused on clinical knowledge, services and tools development for implementation in clinical practise of new treatment methods using whole-plant medical cannabis in combination with personalized medicine tools and integrated care methods.



MIKE LISZEWSKI

Mike Liszewski (J.D., University of the District of Columbia, 2011) is Policy Director at Americans for Safe Access. He spent his early career as a community organizer for Banner Neighborhoods in southeast Baltimore, MD, forming after-school reading, art, sports and employment programs for elementary and middle school-aged youth. As a law student, he helped lead a successful lobbying campaign that defeated an ill-conceived „gang injunction“ bill, and clerked in DC Council Committee on Health as it was considering B18-622, the District’s medical cannabis law. Mike served as a student member of SSDP’s Board of Directors (2010-2012) and the ACLU-NCA (2010-2011). Shortly before joining ASA’s staff, he co-drafted the original version of what was eventually passed and signed into law in D.C. as the Good Samaritan Overdose Prevention Amendment Act of 2012.

As Policy Director at ASA, Mike works with patients, advocates, and elected officials at the state, local and national level to create new laws and improve existing ones that allow patients to have safe access to medical cannabis therapy. In addition to ASA’s legislative work, Mike has also been actively involved with the implementation process to make sure these laws result in patients having legal and affordable access to medicine.



CYNTHIA LUDWIG

Cynthia Ludwig, Director, Technical Services of AOCS, an association that provides technical and scientific resources to the oils, fats, lipids, proteins, surfactants and related industries, is responsible for all Technical Services activities including methods development, ISO Guide 34 accredited Certified Reference Material Program, laboratory proficiency programs, and AOCS accreditations.

Ludwig joined AOCS in 2014. Cynthia has a diverse background and long career as a research scientist. She started her journey as a large scale production and analytical chemist at Sigma-Aldrich in St. Louis, MO. After five years, she joined Monsanto where she spent the next 20 years contributing to over 20 patents, receiving numerous awards and developing new products and technologies. Roundup® production, Celebrex®, Bextra®, Paracoxib, and Decisive and Chipping Technologies are a few of the projects she influenced. Her degrees include a BS in Organic Chemistry from Southern Illinois University and an MS in Physical Organic Chemistry from Eastern Illinois University.

She lives with her small dog Gracie and splits her time between St. Louis MO and Champaign IL.



RYAN C. LYNCH, Ph. D.

Ryan has broad experience with DNA sequencing and analysis technologies—ranging from microbes to prairie grasses to sunflowers. In 2014 he helped launch a Cannabis genome research project at the University of Colorado Boulder. Since completing his Cannabis-based PhD, he has operated a genomics and plant breeding consultancy, and most recently joined Medicinal Genomics. In his current role, he continues to develop genome sequencing technologies for Cannabis cultivators and breeders. These efforts have provided new insight into the diversity and origins many Cannabis varieties from around the globe, and have broad implications for improving the effectiveness and safety of Cannabis-based therapies.



JAHAN MARCU, Ph. D.

Jahan Marcu, Ph. D., is currently the Senior Scientist and Chief Auditor for Americans for Safe Access and the Patient Focused Certification (PFC) Program. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine (IACM). Dr. Marcu is the Director of Research and Development at Green Standard Diagnostics Inc. He received his Ph.D. for significant contributions to the study of the structure and function of the CB1 receptor, and the role of the endocannabinoid system in bone. Before earning his Ph.D., Dr. Marcu worked at the California Pacific Medical Center Research Institute studying the anti-cancer properties of compounds from the cannabis plant (Published in the Journal of Molecular Cancer Therapeutics) and on analytical Cannabis research projects in Holland. He is also an author of the American Herbal Pharmacopoeia Cannabis Monograph and one of the auditors for the Patient Focused Certification (PFC) program; an enforcement and oversight program that ensures that basic product safety protocols are followed at Cannabis operations. Dr. Marcu is a recipient of the Billy Martin research award from the International Cannabinoid Research Society.

SPEAKERS



IAIN MCGREGOR

Iain McGregor is Professor of Psychopharmacology, NHMRC Principal Research Fellow and Director of the Psychopharmacology Laboratory at the University of Sydney. Iain's research focuses on the effects of recreational drugs and prescription drugs on brain and behavior and also involves development of new medications for the treatment of various diseases. His research spans medicinal chemistry, the use of cellular assays and preclinical animal models of disease, and also clinical trials in humans. Major recent areas of research interest include the beneficial effects of oxytocin on social behavior, the development of novel treatments for addiction-related and mental health problems, and analysis of the increasing use of prescription psychotropic drugs in Australia and other countries. Iain has a strong interest in the area of medicinal cannabis and cannabinoids and is Director of Preclinical Research at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, Australia. The Lambert Initiative was established in 2015 with a \$33.7 million philanthropic gift and aims to fast track research into the therapeutic benefits of cannabinoids in various disease states.



BRENT MCKENZIE

Brent McKenzie has served as State Senator Dave Marsden's Legislative Assistant since 2013. Prior to 2013 he served for four years as a member of the Virginia Beach School Board and taught high school in Norfolk, Virginia. Brent is a graduate of Old Dominion University with a B.S. in Political Science and a license to teach social studies. In 2009 Brent was appointed by Governor Tim Kaine and served for one year on Virginia's Advisory Board for Juvenile Justice. As Senator Marsden's Legislative Assistant, Brent has helped lead efforts to pass CBD/THC-A Oil laws in Virginia.



TIMOTHY-PAUL MURPHY

Timothy-Paul Murphy has worked with cannabis his entire professional life. His father was a park ranger and he spent his youth living in state and national parks all over the country. Moving around frequently taught him to make friends quickly and to appreciate many different points of view. At the College of William and Mary, his studies focused on government and the US civil rights movement. Noticing parallels between the Jim Crow era and America's archaic approach to drug policy led him to his first job at the Marijuana Policy Project, where he oversaw a small development team. In 2016, Murphy joined ASA to manage its Patient Focused Certification program. When he's not advocating for the development of a mature and professional marijuana industry, Murphy enjoys playing tennis, blaring rap music, and cooking.



KRISTIN NEVEDAL

Kristin Nevedal is the Director of the Patient Focused Certification Program. Before joining ASA she co-founded and served on the board of the Emerald Growers Association whose mission is to promote the medicinal, environmental, social, and economic benefits of lawfully cultivated sun-grown medical cannabis from California's Emerald Triangle region by advocating for public policies that foster a healthy, sustainable medical cannabis industry. As chair of the American Herbal Products Association (AHPA) Cannabis Committee's Cultivation Working Group, Kristin assisted in the development of cannabis cultivation model regulations and best practices for agency consideration. Kristin is also an instructor at Oaksterdam University, teaching classes on environmental sustainability and Best Management Practices. Kristin's broad policy and advocacy experience also includes serving as a board member for the Coalition for Cannabis Policy Reform (CCPR), Californians to Regulate Medical Marijuana (CRMM), Americans for Safe Access's Patient Focused Certification Program, and the 420 Archives.



PAVEL PACHTA

Dr. Pavel Pachta is an expert in international drug regulation. An economist by education, he lectured at the University of Economics in Prague, Czech Republic, and then served for more than two decades in various positions in the UN drug control bodies. He was between 2004 and 2013 the Deputy Secretary of the International Narcotics Control Board (INCB) at its Headquarters in Vienna, Austria. Dr. Pachta contributed to several UN and WHO publications on substances under international control and their availability for medical and scientific purposes. He has been a drug regulatory control consultant and he lectures internationally on the control of cannabis and cannabinoids. Dr. Pachta is member of the Scientific Board of the International Cannabis and Cannabinoids Institute in Prague. He is member of the Czech Patients Association for Cannabis Treatment „KOPAC“.



STEPHANIE PHILLIPS

Stephanie Phillips is a Senior Legislative Assistant in the Office of Congressman Earl Blumenauer (D-OR), where she has managed marijuana and drug reform policy for nearly four years. During Stephanie's tenure, Congressman Blumenauer -- a national leader in the effort to reform marijuana laws -- has introduced numerous bills, sponsored amendments, and advocated to the Obama Administration to protect medical marijuana businesses and patients who are abiding by state law, as well as reduce barriers to medical marijuana research. She also convenes an informal working group of House staffers interested in broader marijuana reform. Stephanie is from Oregon, a state that has legalized both the adult use and medical use of marijuana. She graduated from New York University, where she studied politics and environmental studies.

**EZRA PRYOR**

As President of Ez Chem Consultancy, Ezra has been interfacing directly with individuals and companies around the globe in the cannabis industry. Ezra has focused on acting as faculty for cannabis educational programs and working directly with those in the cannabis industry to improve their methods and quality of products produced. It is his vision and determination above all else that has made EZ Chem Consultancy the company it is today.

Additionally, Ezra is the founding member and Chair of the Cannabis Chemistry Committee which has endeavored to form a Cannabis Chemistry Technical Division within the American Chemical Society. In an industry where secrets are closely kept and misinformation is abundant, Ezra has been a lab partner for some and a beacon of light for many.

**JEFFREY C. RABER Ph.D.**

Dr. Jeffrey C. Raber received his B.S. in biochemistry from Lebanon Valley College, PA and subsequently a Ph.D. in organic chemistry from the University of Southern California with an emphasis on developing new synthetic methodologies useful in pharmaceutical drug discovery and manufacturing. Dr. Raber studied botanical phylogenetic relationships based on the RuBisCO enzyme's evolution while in college and was named to the USA Today 1997 All-USA College Academic Team for his research accomplishments in this area. While at USC he was awarded the Harold and Lillian Moulton Fellowship for his efforts on the construction of novel heterocycles and peptidomimetics utilizing a proprietary boron-based multicomponent condensation reaction. Since graduate school Dr. Raber has pursued various entrepreneurial endeavors highlighted by KinetiChem where he guides the development and commercialization of a novel continuous flow chemical reactor technology positioned at the forefront of what is called process intensification. Dr. Raber initially joined KinetiChem as the Chief Chemist and quickly became the Vice President and eventually the President and is currently on the company's Board of Directors. Dr. Raber has numerous peer-reviewed publications, including 5 on cannabis chemistry, he has given invited lectures around the world and is also an inventor of multiple patented technologies. Driven by a desire to make a positive contribution to society while creating American jobs Dr. Raber founded The Werc Shop in 2010, an independent laboratory focused on botanical analysis, product development and sustainability with an initial emphasis on serving the unmet public health and safety needs within the medical cannabis community. Dr. Raber's detailed investigations into the chemistry of cannabis as a medicine have provided him with a unique perspective and knowledgebase useful in assisting state and local regulators in the construction and implementation of effective regulatory solutions for the safe and sustainable delivery of medical cannabis to qualified patients. Today The Werc Shop is widely recognized as a leading scientific pioneer and educator in medical cannabis that continues to further everyone's understanding of the plant and its possible product developments. The Werc Shop being guided Dr. Raber is recognized as leading the way towards chemotype designations for strain identification and are creating standardized broad-profile based derivative products through utilization of their innovative solvent-free concentrate processing methods coupled to a novel terpene infusion methodology which allows for the creation of unique and effective cannabis products across many therapeutic categories.

**ETHAN RUSSO**

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system ("ECS"). The PHYTECS team pioneered scientific understanding of how the ECS regulates physiological functions including immunity, pain, inflammation, mood, emotion, learning, memory, metabolism, appetite, weight, sleep, embryo development, neuroprotection and stress responses.

Previously, from 2003-2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy.

He graduated from the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He joined GW as a full-time consultant in 2003.

He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences.

He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over thirty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, and phytocannabinoid/terpenoid, /serotonergic and /vanilloid interactions.



JEANNE SAURO

My name is Jeanne Sauro and I am living with Stage IV Metastatic Breast Cancer. Since becoming a cancer patient I have studied cannabis medicine extensively to treat my cancer and side effects from cancer treatments. I was the first registered student at the first cannabis vocational school in Massachusetts. The name is Northeastern Institute of Cannabis, Natick, MA. I took 11 courses pertaining to medical marijuana. Once I learned about this amazing plant and how it can ease the suffering and even cure some illnesses, I have become a tenacious and driven Medicinal Cannabis Activist. I am currently a Patient Advisory Board Member with Massachusetts Patient Advocacy Alliance and I am working with American's For Safe Access more and more on the national level. I am on the front lines of medicinal marijuana in the state of Massachusetts and am aware of the challenges we face every day being a medical marijuana patient. It has not been easy, but helping to move this important medicine and treatment forward and make it available to all patients is what keeps me going. We are working hard and we are making progress slowly but surely. But we are making History!



STEPH SHERER

Steph Sherer is founder and Executive Director of Americans for Safe Access (ASA), the largest national member-based organization of patients, medical professionals, scientists, and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research.

Her direct experience with the medical benefits of cannabis and her political organizing background led Steph to form ASA in 2002 with the purpose of building a strong grassroots movement to protect patients and their rights. As a powerful advocate, a skilled spokesperson, and an energetic initiator of campaigns, Steph has trained over 100,000 individuals across the country on civic engagement.

Since its inception, ASA has successfully shifted the national debate around medical cannabis, which has focused solely on the legality and ethics of arresting and prosecuting patients for cannabis use, to the real concerns of patients, such as access and civil protections. ASA has worked with lawmakers across the country to adopt and improve medical cannabis legislation and regulatory policy in 34 states and the District of Columbia as well as representing patients on Capitol Hill.

Steph has become the foremost international leader and expert on medical cannabis patient advocacy and, alongside American Herbal Products Association (AHPA), has created the first industry standards in the areas of Distribution, Cultivation, Analytics, and Manufacturing, Packaging and Labeling.



CHRISTINE STENQUIST

Christine Stenquist is a brain tumor patient turned medical cannabis advocate. In 1996, she was diagnosed with an Acoustic Neuroma and removal was attempted; 60% of the tumor remains and with it a host of complications. After a decade and a half of a house-bound and bedridden life she approached her doctor about medical cannabis. Finding cannabis to mitigate most of her symptoms she sought out how to gain access. Being a daughter of a narcotics officer she was faced with the dilemma, break the law or change the law. Utah had passed a highly restrictive CBD only law when She started Drug Policy Project of Utah, a nonprofit dedicated to policy to champion legal access to cannabis in the state of Utah. In 2015, she lobbied and testified in support of SB259 Medical Cannabis Act, which failed in the Senate by one vote. After this narrow loss, Christine's passion was further ignited to see cannabis legislation passed within the State of Utah, and she was determined to make an even greater impact during the following legislative session. Realizing the need for patient lobbyists on Capitol hill, the citizen lobbyist group, TRUCE, Together for Responsible Use and Cannabis Education, was formed to help raise awareness for the need of safe, legal access to cannabis. In the 2016 legislative session, Christine brought patient and caregivers from differing ideologies and conditions together to effectively lobby in support of SB 73, Medical Cannabis Act, outcome yet to be determined. Federal rescheduling of cannabis has also become an area of interest for Christine.



DUSTIN SULAK

Dr. Dustin Sulak is an integrative medicine physician with expertise in osteopathy, mind-body medicine, and medical cannabis. His clinical practice focuses on treating refractory conditions in adults and children with an individualized, health-centered approach. Dr. Sulak received undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine, and completed an osteopathic rotating internship at Maine-Dartmouth Family Medicine Residency. Dr. Sulak is the founder of Integr8 Health, an integrative medicine clinic with 3 locations in New England that treat over 18,000 patients with medical cannabis. He is also the founder of Healer.com, an education and research portal for medical cannabis patients. Dr. Sulak lectures nationally to physicians on the clinical application of cannabinoids and continues to pioneer this emerging field in medicine.



KATE HINTZ

Kate Hintz began her push for advocacy in 2013 after learning that a medical marijuana law had been introduced to the New York State Assembly every year since 1997. "I wanted to be the voice that could help push the bill forward". Kate has a 5 year old daughter that suffers from intractable epilepsy despite trying almost every available anti-seizure drug on the market. She believed that medical cannabis should be the next option in treatment, but had no access in her State. She joined up with a patient advocacy group and began to campaign at every level of her State government. In 2015 Kate and her daughter traveled to Washington DC as the CARERS Bill was introduced, and spoke alongside Senators Kirsten Gillibrand, Corey Booker, and Rand Paul. These days she continues to work on improving and expanding New York State's medical marijuana program. She lives in the suburbs of New York City.



ROY UPTON

Roy Upton, RH, DAYu is the founder, executive director, and editor of the American Herbal Pharmacopoeia (AHP). Roy is also co-founder and past president, of the American Herbalists Guild (AHG), and serves on botanical expert advisory committees of AOAC International, the American Botanical Council, NSF International, and the Lloyd Library and Museum.

Roy has been working and practicing professionally as an herbalist since 1981. He is trained in Ayurvedic, Traditional Chinese, and Western herbal medicine and has also studied and worked extensively with Native American and Caribbean ethnobotanical traditions. As an integral part of his work as an herbalist, Roy spends a great deal of time defending the rights of people to access herbal medicines and to see herbal medicine integrated into the fabric of both our homes and health care systems.

In addition, Roy is the staff herbalist for the California-based herbal supplements company, Planetary Herbals, is a member of the Standards Committee of the American Herbal Products Association, and is an internationally recognized lecturer and author of numerous popular and peer-reviewed scientific publications.



RYAN VANDREY, Ph. D.

Dr. Vandrey is an experimental psychologist with degrees from the University of Delaware (BA) and University of Vermont (PhD). He is currently an Associate Professor at the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU). He has received research grants and contracts from multiple federal agencies, private industry, and non-profit organizations. Dr. Vandrey's research focuses on the behavioral pharmacology of cannabis (marijuana). His research primarily consists of controlled laboratory studies with adult research volunteers, but also includes clinical trials, web-based survey research, and natural history studies with patient populations using cannabis/cannabinoids for therapeutic purposes. Prior research includes laboratory studies characterizing the cannabis withdrawal syndrome, evaluation of the comparative pharmacokinetics and corresponding pharmacodynamics of cannabinoids across routes of administration, exploring medications that can be used as adjuncts to behavior therapy to improve rates of abstinence among individuals trying to quit using cannabis, examining the effects of cannabis on sleep, and conducting research designed to help evaluate the safety and efficacy of medicinal use of cannabis/cannabinoids for specific health conditions.



BOAZ WACHTEL

Boaz Wachtel is an Initiator (1995-2013) and co-strategist with Israel's Ministry of Health (MOH) of Israel's Medical Cannabis program that currently includes over 11,000 patients served by eight specialist physicians authorized to issue licenses and eight licensed cultivators. A researcher on addiction, harm reduction, and cannabis, he has published more than two dozen articles, papers, and book chapters. He was a founding member of the 'Israeli Foundation for Drug Law Reform' (1994) and a public representative to the Knesset (Israeli Parliament) Drug Committee "Examining the legal status of Cannabis." He submitted to the MOH the cannabis 'Drug Master File' (safety and efficacy data) and has since represented patients to the MOH which established in 1999 a committee to review requests and provide licenses for patients to possess medicinal cannabis. He was a co-producer with Maripharma Holland of „The Medicinal Uses of Cannabis“ from 2000-2002, and an organizer with MOH of the Medical Cannabis Education Seminar for Doctors in 2007. In 2009, he became a founding member (volunteer) of the Centralized National Medical Cannabis distribution Center in Abarbanel Hospital. He has been a Member of the Board of the Israeli AIDS committee since 2006 and is a Member of the Steering Committee of ENCOD, the European Coalition for Just and Effective Drug Policies. He is a founder and former Chairman (1999-2006) of Israel's Green Leaf Party, which won 1% of the national vote in 1999, 1.2% in 2003 and 1.4% in 2006. He was an addiction treatment provider using Ibogaine (1989-2000) and co-author, with Howard Lotsof, of the „Ibogaine - Treatment Manual.“ He currently works developing agricultural technologies. Boaz is a Certified Clinical Research Administrator with Israel's MOH and Bar-Ilan University, and is a certified Consultant with the EU Research & Development Program at Tel Aviv University. He served as Assistant Army Attaché' in the Israeli Embassy in DC from 1983-1988.



GRACE WALLACK

Grace Wallack is a Senior Research Assistant at the Center for Effective Public Management at The Brookings Institution and Associate Editor of the FixGov blog. She works on regulatory policy, presidential and congressional elections, and institutional effectiveness. She is the co-author, with John Hudak, of the report, "Ending the U.S. government's war on medical marijuana research." She holds a B.A. in American Studies from Georgetown University.

SPEAKERS



Dr. MARK A. WARE MBBS MRCP(UK) MSc

Dr. Mark Ware is Associate Professor in Family Medicine and Anesthesia at McGill University. He is the Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre, co-Director of the Quebec Pain Research Network, Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids (CCIC) and chair of the International Association for Cannabinoids Medicines (IACM). He practices pain medicine at the Montreal General Hospital and at the primary care pain clinic of the West Island of Montreal.

Dr Ware’s primary research interests are in evaluating the safety and effectiveness of medicines derived from cannabis (cannabinoids), population-based studies of the impact of pain on the population, and the role of complementary therapies in pain and symptom management. His research is funded by the FRSQ, CIHR, and the Louise and Alan Edwards Foundation.

A graduate of the University of the West Indies (MBBS 1992), Dr. Ware worked at the MRC Sickle Cell Unit in Kingston Jamaica from 1996-1998 where he developed his interests in pain management and cannabis therapeutics. He moved to McGill University in Montreal, Canada in 1999 and since then has secured the only two Canadian federal grants to study medical cannabis. He has published over 70 papers on pain and cannabis, 6 book chapters, and given over 150 scientific talks to local, national and international audiences. He has served as an advisor to the Canadian government since 2001 on medical cannabis policy.



MELISSA WILCOX

Melissa Wilcox is a Global Marketing Manager for Grace Discovery Sciences. She has more than 20 years experience in chromatographic separations, with expertise in analytical chromatography and purification technologies. She holds patents on evaporative light scattering detection technology and is involved in research and development, applications development, business development, and marketing. Melissa is a co-founder and Counselor for the American Chemical Society (ACS) Cannabis Chemistry subdivision (CANN) and a member of the American Oil Chemists Society (AOCS) and American Herbal Products Association (AHPA) cannabis expert panels. She is part of a collaborative research team working to develop better analytical methods for cannabis products to ensure patient safety, focusing on sample preparation of edible products with complex matrices.



JANE WILSON

Jane Wilson is the Director of Program Development for the American Herbal Products Association (APHA) where her duties include working with the AHPA management team to develop, implement, and manage AHPA programs and services. She brings to this role many years of experience developing cooperative relationships with representatives of industry, trade associations, public health officials, regulatory bodies, advocacy groups, and other stakeholders.

Since joining the staff of AHPA in 2013, Jane has been providing staff support to the AHPA Cannabis Committee in its development of a series of “Recommendations to Regulators” documents that define best practices for the cannabis industry from seed to consumer. These documents are being provided to regulators in states where use of cannabis has been legalized so that regulatory authorities can consider the adoption of these recommendations, in whole or in part, as the basis for development of jurisdiction-specific regulations. These documents also provide the foundation for the ASA Patient Focused Certification (PFC) Program and can be used by those in the cannabis industry seeking to self-regulate on cannabis product safety and quality.

Jane has more than 25 years of experience in various positions related to protection of public health and the environment. She holds a Master of Public Health degree in Toxicology and a Bachelor of Science degree in Medical Technology, both earned at the University of Michigan.



ASA 2016 EXCELLENCE AWARD WINNERS

- **Patient Advocate of the Year:** Terrie Best
- **Patient Lobbyist of the Year:** Yami Bolanos
- **Elected Official of the Year:** Georgia State Representative Allen Peake
- **Elected Official of the Year:** Senator Cory Booker
- **Elected Official of the Year:** Senator Kirsten Gillibrand
- **Action Group of the Year:** Georgia's Hope
- **ASA Chapter of the Year:** Sonoma County
- **Researcher of the Year:** Dr. Marcel Bonn-Miller
- **Medical Professional of the Year:** Meredith Fisher-Corn, MD
- **Journalist of the Year:** Tony Dreibus
- **Courage Award Winner:** Christine Stenquist
- **Lifetime Award Winner:** Lumir Hanus



Award Descriptions

PATIENT ADVOCATE OF THE YEAR:

Terrie Best

Awarded to an advocate who represents the patient perspective in every aspect of their work. Patient Advocate awardees are respected in their communities and are the definition of a compassionate individual.

PATIENT LOBBYIST OF THE YEAR:

Yami Bolanos

Awarded to an individual who has demonstrated great success in the last year through their legislative and lobbying efforts.

ELECTED OFFICIALS OF THE YEAR:

Representative Allen Peake, Senators Gillibrand and Booker

Awarded to elected officials who have been compassionate towards medical cannabis at either the local, state, or federal level.

ACTION GROUP OF THE YEAR:

Georgia's Hope

Awarded to the ASA Action Group that has distinguished itself by being extremely involved in their communities and are particularly effective in local and state campaigns.

ASA CHAPTER OF THE YEAR:

Sonoma County

Awarded to the ASA Chapter that has distinguished itself by being extremely involved in their local communities and holding successful education and fundraising events.

RESEARCHER OF THE YEAR:

Dr. Marcel Bonn-Miller

Awarded to a researcher who has contributed outstanding findings in the field of medical cannabis.

MEDICAL PROFESSIONAL OF THE YEAR:

Meredith Fisher-Corn, MD

Awarded to a medical professional who has displayed great leadership advancing the cause of medical cannabis. This leadership often comes in the form of outreach, education, and research.

JOURNALIST OF THE YEAR:

Tony Dreibus

Awarded to journalists or media personalities who have raised the national dialogue regarding medical cannabis.

COURAGE AWARD WINNER:

Christine Stenquist

Awarded to an advocate who has displayed great courage in the face of adversity. Often our Courage awardees are new to advocacy but due to their passion they are able to enact great change in a short time.

Choose Cannabis Therapeutics with Confidence

Look for
the PFC Seal



What is PFC?

Patient Focused Certification (PFC) is a non-profit, third-party certification for medical cannabis products and services offered by Americans for Safe Access (ASA). The PFC means that products and services have been Verified through the rigorous audit process based on new quality standards issued by the American Herbal Products Association (AHPA) and the American Herbal Pharmacopoeia (AHP).



To find PFC verified products and services
visit patientfocusedcertification.org

Patient Focused Certification means:

- ✓ Company staff are well trained
- ✓ Products and services have been tested for contaminants
- ✓ Products and services meet legal requirements as well as AHPA & AHP standards
- ✓ Companies have recall protocols in place

ASA HEADQUARTERS STAFF

OFFICE OF THE EXECUTIVE DIRECTOR



Steph Sherer
Executive Director



Debbie Churgai
Assistant to the
Executive Director

OPERATIONS



Talana Lattimer
Operations Director



Geoffrey Marshall
Office & Membership
Coordinator

PUBLIC POLICY



Beth Collins
Communications &
Outreach Director



Mike Liszewski
Government Affairs
Director



Don Duncan
California Director



Aria Mildice
National Field Liaison

PATIENT FOCUSED CERTIFICATION



Kristin Nevedal
PFC Program Director



Jahan Marcu, PhD
Chief Auditor & Senior
Scientist



Timothy-Paul Murphy
PFC Program Manager

TheAnswerPage™
Learn something every day™
Interactive Crossword Puzzle for
AMA PRA Category 1 CME Credits™
LEARN MORE >>

For Industry

**"TheAnswerPage is the
medical marijuana educational
resource recommended by the
Americans for Safe Access."**

THEANSWERPAGE is expert at creating customized medical marijuana educational programs focused on relevant medical and legal issues. With our international team of authors, researchers and clinicians, TheAnswerPage develops live and on-line events to fulfill the advertising and educational needs of any organization, healthcare entity, or medical society.

TheAnswerPage has created proprietary "CME Credit Cards" to "Get You in Front, And Keep You in Front" of your business audience!

On a daily basis, TheAnswerPage's Newsletter and compelling "Question of the Day" can carry your brand to the inbox of doctors, pharmacists and nurses around the globe, and to every healthcare provider who has registered for the "New York State Practitioner Education-Medical Use of Marijuana Course."

Simply contact our team at Info@TheAnswerPage.com and we'll Get you in Front and Keep you in Front of audiences that only TheAnswerPage can reach!

TheAnswerPage is a recognized leader for the creation of comprehensive educational courses focused in medical marijuana, opioid therapy and pain medicine. The courses fulfill the medical marijuana educational needs of doctors, pharmacists, nurses and other healthcare providers, hospital systems, state medical societies, dispensaries and patients on a daily basis nationwide. TheAnswerPage's editorial team is comprised of Harvard Medical School trained physicians. The "Founding Editor-in Chief" and the presiding "Editor-in-Chief" have each been named "Medical Professional of the Year" by the Americans for Safe Access for seminal work in advancing medical marijuana education. This medical education resource has been providing quality content to a worldwide audi-

ence since 1998, has granted well over 100,000 hours of AMA PRA Category 1 CME Credits™ and has been featured in the *New England Journal of Medicine*.

TheAnswerPage is uniquely distinguished for being selected to be the sole education provider for the only two US states with a specific required medical marijuana educational curriculum:

"New York State Practitioner Education-Medical Use of Marijuana Course."

"Florida Physicians Low-THC Cannabis Course."

TheAnswerPage has received thousands of positive letters from around the world...here are just two recent ones:

"Thank you for providing the NYS Practitioner Education for Medical Use of Marijuana certification course! I have just completed the course and have found it very comprehensive, informative, and engaging. I am satisfied with the way that the course material was presented and believe that it will be extremely useful to my future practice. I hope to continue to have access to the material in the future. The crossword puzzle at the end of each topic was a great way to break up the lecture material and I found that it helped solidify important points. Looking forward to venturing into this new industry."

*Best Regards,
Laura C, PharmD*

"The Florida Medical Association and Florida Osteopathic Medical Association wish to thank The Answer Page, Inc. (TAP) for serving as our educational partner in creating this low THC cannabis course for the physicians of Florida. TAP has pioneered quality innovative on-line education."

TheAnswerPage™
Learn something every day™
Interactive Crossword Puzzle for
AMA PRA Category 1 CME Credits™
LEARN MORE >>

For Healthcare Providers

**"TheAnswerPage is the
medical marijuana educational
resource recommended by the
Americans for Safe Access."**

THEANSWERPAGE has been providing medical educational content worldwide since 1998. TheAnswerPage is now read in over 120 countries, has granted well over 100,000 hours of AMA PRA Category 1 CME Credits™ and offers an industry-unique interactive CME crossword puzzle for a fun and effective learning experience.

TheAnswerPage has become a recognized leader in the creation of comprehensive educational courses focused in medical marijuana, opioid therapy and pain medicine for doctors, nurses, pharmacists and other healthcare professionals.

Interested? Simply go to TheAnswerPage.com and click on "Study Now" to explore these compelling topics in the "Medical Education Library." Registration is free and your personal information is never shared!

As an added educational feature, TheAnswerPage provides a compelling "Question of the Day" focused among topics of medical marijuana, opioid treatment and pain medicine.

TheAnswerPage is comprised of a Harvard Medical School trained editorial team where the "Founding Editor-in Chief" and the presiding "Editor-in-Chief" have each been named "Medical Professional of the Year" by the Americans for Safe Access for seminal work in advancing medical marijuana education.

TheAnswerPage has been featured in the *New England Journal of Medicine*.

TheAnswerPage is uniquely distinguished for being selected to be the sole education provider for the only two US states with a specific required medical marijuana educational curriculum:

"New York State Practitioner Education-Medical Use of Marijuana Course."

"Florida Physicians Low-THC Cannabis Course."

TheAnswerPage has received thousands of positive letters from around the world...here are just two recent ones:

"Thank you for providing the NYS Practitioner Education for Medical Use of Marijuana certification course! I have just completed the course and have found it very comprehensive, informative, and engaging. I am satisfied with the way that the course material was presented and believe that it will be extremely useful to my future practice. I hope to continue to have access to the material in the future. The crossword puzzle at the end of each topic was a great way to break up the lecture material and I found that it helped solidify important points. Looking forward to venturing into this new industry."

*Best Regards,
Laura C, PharmD*

"The Florida Medical Association and Florida Osteopathic Medical Association wish to thank The Answer Page, Inc. (TAP) for serving as our educational partner in creating this low THC cannabis course for the physicians of Florida. TAP has pioneered quality innovative on-line education."

Contact us at Info@TheAnswerPage.com

Save the Date



5TH
ANNUAL
NATIONAL
MEDICAL
CANNABIS
UNITY
CONFERENCE
2017

APRIL 7-11, 2017
LOEWS MADISON HOTEL
1177 15TH ST
WASHINGTON, DC 20005




www.NationalMedicalCannabisUnityConference.org

CONFERENCE LOCATION



MARCH 18-22, 2016
LOEWS
MADISON HOTEL,
WASHINGTON, D.C.



44



45



NOTES



UNITY 2016 SPONSORSHIP

PRESENTING SPONSOR

DIOSCORIDES



EMERALD SPONSOR



GOLD SPONSOR



SILVER SPONSOR






BRONZE SPONSOR



EDUCATIONAL SPONSOR



 facebook.com/safeaccessnow
 twitter.com/safeaccess
 plus.google.com/+AmericansforSafeAccess

Q&A/ Information:
conference@safeaccessnow.org

Contact for media representatives:
press@safeaccessnow.org

The conference is organized by Americans for Safe Access

Address: 1624 U Street NW
Suite 200
Washington, DC 20009

© Americans for Safe Access, 2016; design: Missing Element Prague

